Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

1130

10.17650/1726-9776-2007-3-4-6-11

LECTURE

ЛЕКЦИЯ

Target therapy for disseminated renal cancer

Таргетная терапия распространенного рака почки

Alekseyev

B. Ya.

Алексеев

Б. Я.

Russian Federation

Shegai

P. V.

Шегай

П. В.

Russian Federation

МНИОИ им. П.А. Герцена

30122007

6111602202016022020

https://oncourology.abvpress.ru/oncur/article/view/1130

1. Godley P.A., Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001;13:199—203.

Godley P.A., Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001;13:199—203.

2. Jemal A., Tiwari R.C., Murray T. et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54(1):8—29.

Jemal A., Tiwari R.C., Murray T. et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54(1):8—29.

3. Чиссов В.И., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2005 году. М.; 2007.

Чиссов В.И., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2005 году. М.; 2007.

4. Janzen N.K., Kim H.L., Figlin R.A., Belldegrun A.S. Surveilance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30(4):843—52.

Janzen N.K., Kim H.L., Figlin R.A., Belldegrun A.S. Surveilance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30(4):843—52.

5. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289—96.

Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289—96.

6. Motzer R.J., Bacik J., Schwartz L.H. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454—63.

Motzer R.J., Bacik J., Schwartz L.H. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454—63.

7. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408—17.

Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408—17.

8. Fojo A.T., Shen D.W., Mickley L.A. et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987;5:1922—7.

Fojo A.T., Shen D.W., Mickley L.A. et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987;5:1922—7.

9. Ernest S., Rajaraman S., Megyesi J. et al. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997;77:284—9.

Ernest S., Rajaraman S., Megyesi J. et al. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997;77:284—9.

10.

10. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999;353:14—7.

Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999;353:14—7.

11.

11. Huland E., Heinzer H.Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer 2000;82:246—7.

Huland E., Heinzer H.Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer 2000;82:246—7.

12.

12. Atzpodien J., Kirchner H., Illiger H.J. et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85:1130—6.

Atzpodien J., Kirchner H., Illiger H.J. et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85:1130—6.

13.

13. Vogelzang N.J., Priest E.R., Borden L. Spontaneous regression of hystologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 1992;148:1247—8.

Vogelzang N.J., Priest E.R., Borden L. Spontaneous regression of hystologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 1992;148:1247—8.

14.

14. Oliver R.T.D., Mehta A., Barnett M.J. A phase 2 study of surveillance in patients with metastatic renal cell and assessment of response of such patients to therapy on progression. Mol Biother 1998;1:14—20.

Oliver R.T.D., Mehta A., Barnett M.J. A phase 2 study of surveillance in patients with metastatic renal cell and assessment of response of such patients to therapy on progression. Mol Biother 1998;1:14—20.

15.

15. McDermott D.F., Regan M.M., Clark J.L. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133—41.

McDermott D.F., Regan M.M., Clark J.L. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133—41.

16.

16. Yang J.C., Sherry R.M., Steinberg S.M. et al. Randomized study of high-dose and lowdose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127—32.

Yang J.C., Sherry R.M., Steinberg S.M. et al. Randomized study of high-dose and lowdose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127—32.

17.

17. Coppin C., Porzsolt F., Awa A. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425.

Coppin C., Porzsolt F., Awa A. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425.

18.

18. Bergers G., Song S., Meyer-Morse N. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9): 1287—95.

Bergers G., Song S., Meyer-Morse N. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9): 1287—95.

19.

19. Maxwell P.H., Wiesener M.S., Chang G.W. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 1999;399:271—5.

Maxwell P.H., Wiesener M.S., Chang G.W. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 1999;399:271—5.

20.

20. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2(9):673—82.

Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2(9):673—82.

21.

21. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028—13.

Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028—13.

22.

22. de Paulsen N., Brychzy A., Foumier M.C. et al. Role of transforming growth factoralpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98:1387—92.

de Paulsen N., Brychzy A., Foumier M.C. et al. Role of transforming growth factoralpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98:1387—92.

23.

23. Gollob J.A., Wilhelm S., Carter C. et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ ERK signal transduction pathway. Semin Oncol 2006;33:392—406.

Gollob J.A., Wilhelm S., Carter C. et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ ERK signal transduction pathway. Semin Oncol 2006;33:392—406.

24.

24. Schwartz G., Dutcher J.P., Vogelzang N.J. et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer. Proc Am Soc Clin Oncol 2002;21:24a (abstr 91).

Schwartz G., Dutcher J.P., Vogelzang N.J. et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer. Proc Am Soc Clin Oncol 2002;21:24a (abstr 91).

25.

25. Ravaud A., Gardner J., Hawkins R. et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006;24(Suppl.):217s (abstr 4502).

Ravaud A., Gardner J., Hawkins R. et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006;24(Suppl.):217s (abstr 4502).

26.

26. Hudes G., Carducci M., Tomczac P. et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24(Suppl):2S (abstr LBA4).

Hudes G., Carducci M., Tomczac P. et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24(Suppl):2S (abstr LBA4).

27.

27. Motzer R.J., Amato R., Todd M. et al. Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:99—101.

Motzer R.J., Amato R., Todd M. et al. Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:99—101.

28.

28. Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505—12.

Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505—12.

29.

29. Yang J.C., Haworth L., Sherry R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427—34.

Yang J.C., Haworth L., Sherry R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427—34.

30.

30. Hurwitz H., Dowlati A., Savage S. et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. J Clin Oncol 2005;23(Suppl 16S):195s (abstr 3012).

Hurwitz H., Dowlati A., Savage S. et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. J Clin Oncol 2005;23(Suppl 16S):195s (abstr 3012).

31.

31. Motzer R.J., Michaelson M.D., Redman B.G. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16—24.

Motzer R.J., Michaelson M.D., Redman B.G. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16—24.

32.

32. Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516—24.

Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516—24.

33.

33. Motzer R.J., Hutson T.E. Tomczac P. et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl):2S (abstr LBA3).

Motzer R.J., Hutson T.E. Tomczac P. et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl):2S (abstr LBA3).

34.

34. Amato R.J., Misellati A., Khan M. et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl.):224S (abstr 4530).

Amato R.J., Misellati A., Khan M. et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl.):224S (abstr 4530).

35.

35. Wilhelm S., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Clin Cancer Res 2004;64:7099—109.

Wilhelm S., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Clin Cancer Res 2004;64:7099—109.

36.

36. Awada A., Hendlisz A., Gil T. et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92(10):1855—61.

Awada A., Hendlisz A., Gil T. et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92(10):1855—61.

37.

37. Strumberg D., Richly H., Hilger R.A. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965—72.

Strumberg D., Richly H., Hilger R.A. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965—72.

38.

38. Escudier B., Szczylik C., Demkow T. et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment naive patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl):18S (abstr 4501).

Escudier B., Szczylik C., Demkow T. et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment naive patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl):18S (abstr 4501).

39.

39. Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal carcinoma. N Engl J Med 2007;356:125—34.

Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal carcinoma. N Engl J Med 2007;356:125—34.

40.

40. Elsen T., Bukowski R.M., Staehler M. et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol 2006; 24 (Suppl):223S (abstr 4524).

Elsen T., Bukowski R.M., Staehler M. et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol 2006; 24 (Suppl):223S (abstr 4524).

41.

41. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115—24.

Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115—24.